Acorda Therapeutics (ACOR) Tops Q4 EPS by 6c
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Financial Fact:
Operating income (loss): -5.47M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Operating income (loss): -5.47M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $130.9 million versus the consensus estimate of $128.24 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- The LGL Group (LGL) Misses Q2 EPS by 8c
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
